UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2016	Oct. 31, 2015
Operating revenue:
Personalized oncology solutions	$ 497	$ 486	$ 1,007	$ 971
Translational oncology solutions	3,960	2,485	7,119	4,822
Total operating revenue	4,457	2,971	8,126	5,793
Costs and operating expenses:
Cost of personalized oncology solutions	374	568	847	1,228
Cost of translational oncology solutions	1,829	1,443	3,879	3,056
Research and development	1,008	919	2,219	2,019
Sales and marketing	717	834	1,643	1,863
General and administrative	1,022	1,700	2,555	3,017
Total costs and operating expenses	4,950	5,464	11,143	11,183
Loss from operations	(493)	(2,493)	(3,017)	(5,390)
Other (expense):
Other (expense)	(16)	(14)	(25)	(24)
Total other (expense)	(16)	(14)	(25)	(24)
Loss before provision for income taxes	(509)	(2,507)	(3,042)	(5,414)
(Benefit from) Provision for income taxes	(5)	41	9	47
Net loss	$ (504)	$ (2,548)	$ (3,051)	$ (5,461)
Net loss per common share outstanding
Net loss per common share outstanding, basic and diluted (in dollars per share)	$ (0.05)	$ (0.29)	$ (0.32)	$ (0.63)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic and diluted (in shares)	10,967,491	8,702,237	9,560,088	8,702,237